image credit- shutterstock
Grünenthal, a global leader in pain management and research, and DKSH Business Unit Healthcare, a strategic healthcare business partner and leading provider of Market Expansion Services for pharmaceutical, over-the-counter (OTC), consumer health and medical device companies, have announced a new partnership agreement to bring four Grünenthal medicines, Qutenza®, Vimovo®, Palexia® and Zomig®, to Asia-Pacific (APAC), accelerating access to innovative pain therapies in the region.
The partnership will support the availability of Grünenthal's pain medicines across eight markets in Asia-Pacific: Hong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand and Vietnam, bringing up to four new medicines to patients in each market, pending local regulatory approvals.
Under the agreement, DKSH will commercialise the medicines on Grünenthal's behalf across the eight markets, being responsible for seeking local marketing authorisations and the activities of marketing, medical, market access, sales and distribution. Grünenthal will manufacture the medicines through its integrated global manufacturing network.
Pain is a significant healthcare challenge in Asia-Pacific, due to the ageing population and the high burden of chronic diseases. Hundreds of millions of people in the region may be living with chronic pain, based on population figures and global estimates of chronic pain prevalence.
